| ²é¿´: 963 | »Ø¸´: 2 | |||
Ò©¶É
|
[½»Á÷]
FDA Åú×¼GileadµÄÖÎÁÆÂýÐÔ±ûÐ͸ÎÑ×Harvoni ® ÒÑÓÐ2È˲ÎÓë
|
|
www.pharmacodia.com GileadÓÚ2015Äê11ÔÂ12ºÅÐû²¼£¬ FDA ÒÑÅú×¼ Harvoni ® (ledipasvir/sofosbuvir) À©´óʹÓûùÒò4¡¢ 5 ºÍ 6 ÐÍÂýÐÔ±ûÐ͸ÎÑײ¡¶¾ (HCV) ¸ÐȾ»¼ÕߺÍͬʱ¸ÐȾ°¬×̲¡¶¾µÄ»¼Õß¡£´ËÍ⣬24 ÖÜµÄ Harvoni ±¸ÓÃÖÎÁƸÎÓ²»¯µÄÖÎÁƾÀú£¬»ùÒò 1 ÐÍ»¼Õß²¢°éÓиÎÓ²»¯£¬¿ÉÒÔ½»ÌæÖÎÁÆ·½°¸Harvoni ¼Óribavirin(RBV) Ϊ 12 ¸öÐÇÆÚµÄ·½°¸ÖÎÁÆ¡£Harvoni ÔÚ 2014 Äê 10 ÔÂÔÚÃÀ¹úÊÕµ½¼à¹Ü²¿ÃŵÄÅú×¼£¬ÓÃÓÚ³ÉÈËÖÎÁÆÂýÐÔ±ûÐ͸ÎÑײ¡¶¾»ùÒò1Ð͸ÐȾ¡£ Ñо¿ºÍ·¢Õ¹Ö´Ðи±×ܲüæÊ×ϯִÐйÙNorbert Bischofberger, Ph.D.˵'Harvoni ÊÇÖÎÁÆHCVµÄµÚÒ»¸öÒ²ÊÇΨһ¸öÊÇÆ¬¼ÁµÄÒ©ÎÑÓÐø¸ßµÄÖÎÓúÂʲ¢ÇÒ´óÖÚ»¼Õß¿ÉÒÔ½ÓÊܵĸ±×÷Ó㬰üÀ¨ÄÇЩÔÚÀúÊ·ÉÏÒ»Ö±±»ÊÓΪÊôÓÚ×îÄÑÖÎÓúµÄ»¼Õß¡£ÎÒÃǺܸßÐË HarvoniÄÜΪ±ûÐ͸ÎÑ×»¼ÕßÈËȺ°üÀ¨ÎÀÉú±£½¡ÌṩÕßÔÚÆäʹÓÃÉϵÄÌṩָµ¼¡£¡± »ùÒò4¡¢ 5 ºÍ 6 ÐÍ HCV»ùÒò4-6 Ð͵ıØÐëÓÐopen-label trials 1119ºÍELECTRON-2ÌṩµÄÊý¾ÝÖ§³Å£¬²ÅÄÜ»ñµÃ²¹³äÐÂÒ©ÎïÓ¦Óà (sNDA) µÄÅú×¼¡£1119Ñо¿HarvoniÔÚHCV»ùÒò4 »ò 5Ð͵ϼÕß½øÐÐΪÆÚ12ÖܵÄÖÎÁÆ£¬ÆäÖУ¬ÕâЩ»¼ÕßÊÇûÓÐÖÎÁƾÀú»òÕßÓÐÖÎÁƾÀú°éÓлòÕßû°éÓиÎÓ²»¯µÄ»¼Õß¡£½á¹ûÏÔʾ£¬ 93%(41/44) µÄ»ùÒòÐÍ 4 £¬93%(38/41) µÄ»ùÒòÐÍ 5 È¡µÃÁË SVR12¡£ELECTRON-2Ñо¿HarvoniÔÚHCV»ùÒòÐÍ 6µÄ»¼Õß½øÐÐΪÆÚ12ÖܵÄÖÎÁÆ£¬ÆäÖУ¬ÕâЩÑо¿¶ÔÏóÊÇûÓÐÖÎÁƾÀú»òÕßÓÐÖÎÁƾÀúµÄ»¼Õß¡£ÔÚ´ËÑо¿ÖУ¬96%(24/25) »¼Õß´ïµ½ SVR12¡£ ×î³£¼û²»Á¼Ê¼þ (ÖÁÉÙ 10%µÄÊÜÊÔÕß) ÐéÈõ (18%)¡¢ Í·Í´ (14%) ºÍÆ£ÀÍ (10%)¡£ HCV»¼Õßͬʱ¸ÐȾ°¬×̲¡¶¾ ÃÀ¹ú´óÔ¼ÓÐ30%¸ÐȾHIVµÄ²¡ÈËÊDZûÐ͸ÎÑײ¡¶¾/°¬×̲¡¶¾ÁªºÏ¸ÐȾ»¼Õß¡£Ïà±Èµ¥´¿µÄ±ûÐ͸ÎÑײ¡¶¾¸ÐȾ£¬HIV ºÍHCV¹²Í¬¸ÐȾµÄ»¼Õ߸ÎÓ²»¯µÄ·çÏÕÔö¼ÓºÍÖÕÄ©ÆÚ¸Î²¡Ïà¹Ø¼²²¡ºÍ¸Îϸ°û°© (¸Î°©)²¢·¢Ö¢Ôö¶à¡£ HIV-1 ºÍHCV¹²Í¬¸ÐȾµÄ»¼Õߣ¬ÔÚ sNDA ¸ù¾ÝÁÙ´²3ÆÚopen-label ION-4Ñо¿Êý¾ÝÓèÒÔÅú×¼¡£ÆÀ¹ÀHarvoni Ó¦ÓÃÔÚ»ùÒò4¡¢ 5 ºÍ 6 Ð͵ĻùÒòÐÍÂýÐÔHCV¸ÐȾ»¼ÕߺÍHIV ºÍHCV¹²Í¬¸ÐȾµÄ»¼ÕßµÄЧ¹û£¬Êý¾ÝÏÔʾ£¬96%(321/335) »¼Õß´ïµ½ SVR12¡£ÕâÏÑо¿°üÀ¨HCVÖÎÁÆ-ÎÞÖÎÁƾÑé (45%) ºÍÓÐÖÎÁƾÀú (55%) »¼Õߣ¬°üÀ¨¸ÎÓ²»¯ (20%) µÄÕß¡£´ó¶àÊý»¼ÕßÕýÔÚÈý¸ö°¬×̲¡¶¾¿¹Äæ×ªÂ¼²¡¶¾ (ARV) ·½°¸Ö®Ò»: tenofovir disoproxil fumarate (TDF) ºÍefavirenz (Atripla® ¡¢ raltegravir or rilpivirine (Complera® ¡£×î³£¼ûµÄ²»Á¼·´Ó¦(ÔÚÖÁÉÙ 10%µÄÊÜÊÔÕß) ÊÇÍ·Í´ (20%) ºÍÆ£ÀÍ (17%)¡£ ÓÐÖÎÁƸÎÓ²»¯¾ÀúµÄ»¼Õß sNDA Åú×¼ÁËHarvoni µÄÖÎÁƼÓÉÏRBVµÄÖÎÁƶԻùÒò1ÐÍ HCV²¢ÓÐÖÎÁƾÀú°éËæ¸ÎÓ²»¯»¼Õß½øÐÐΪÆÚ 12 ÖÜÁÙ´²2ÆÚµÄ SIRIUS Ñо¿¡£ÆÀ¹À Harvoni ¼Ó RBV £¬12 ÖÜ»òûÓÐ RBVÇé¿öÏ£¬ Harvoni ÓÚ24 ÖܶԻùÒò1ÐÍHCV»¼Õ߸ÎÓ²»¯ÊÂÏÈÖÎÁÆÊ§°ÜµÄ»¼ÕßÊý¾ÝÖ§³Ö¡£96%µÄ»¼ÕßÖÎÁÆ 12 ÖÜ£¬Harvoni ¼Ó RBV (74/77) %ºÍ 97%(75/77) µÄ»¼ÕßÖÎÁÆ 24 ÖÜHarvoniÎÞ RBV£¬´ïµ½ SVR12¡£ ×î³£¼ûµÄ²»Á¼·´Ó¦ (·¢ÉúÔÚÖÁÉÙ 10%µÄÊÜÊÔÕß) £¬ÔÚ12ÖÜÄÚ£¬ ½ÓÊÜ Harvoni ¼Ó RBV »¼Õß³öÏÖÐéÈõ (36%)¡¢ Í·Í´ (13%)¡¢ ¿ÈËÔ (11%)¡£24 ÖÜÄÚ£¬½ÓÊÜ Harvoni µÄ»¼Õߣ¬ÐéÈõ (31%)¡¢ Í·Í´ (29%) ºÍÆ£ÀÍ (18%)¡£ Å·ÖÞÒ©Æ·¾Ö£¨EMA£©×î½ü»¹Åú×¼ÔÊÐíʹÓà Harvoni ºÍ RBV ÁªºÏʹÓ㬵«ÁªºÏʹÓÃʱ¼ä½Ï¶Ì¡£¾ßÌå½²£¬ÕâЩ°üÀ¨ÎªÆÚ 12 ÖÜµÄ Harvoni ¼Ó RBV Ó¦ÓÃÓÚ»ùÒò1ºÍ4ÐÍHCVȾ»¼Õß²¢°éÓиÎÓ²»¯ºÍ¸ÎÒÆÖ²»¼Õß¡£Êý¾Ý½øÒ»²½Ö§³Ö 12 ÖÜ Harvoni ÓÃÓÚ»ùÒò1 »ò 4 ÐÍ»¼Õߣ¬Í¬Ê±¸ÐȾÁËHIVµÄ»¼ÕߺÍÄÇЩÒÔǰÓÃsofosbuvir¼Ó RBV ÓлòûÓоÛÒÒ¶þ´¼¸ÉÈÅËØÖÎÁÆÖÎÁÆÊ§°ÜµÄ»¼Õß¡£ |
» ²ÂÄãϲ»¶
[ÇóÖú] Á÷ʽËÀ»îȾ & µ¥Ï¸°ûÃÅ¿ØÉèÖñ»ÖÊÒÉ£¬ÈçºÎÓÅ»¯²¢½âÊÍ£¿
ÒѾÓÐ1È˻ظ´
µ°°×Îȶ¨ÐÔʵÑéÓ빦ÄÜʵÑé²»Ò»ÖÂ
ÒѾÓÐ11È˻ظ´
Ò©ÀíѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ106È˻ظ´
µÚ4ÄêÁË£¬ÂíÉÏ40ÁË£¬¿ÉÄÜÎÒÓë¹ú»ùȷʵÎÞÔµ°É¡£¡£¡£
ÒѾÓÐ12È˻ظ´
26ÓÐûÓÐÀÏʦÏëÊÕ×ö¶¨Á¿Ò©ÀíµÄѧÉú°¡
ÒѾÓÐ3È˻ظ´
2026ÄêÉ격ҩѧרҵ
ÒѾÓÐ1È˻ظ´
26¿¼²©ÉêÇë ѧorר
ÒѾÓÐ15È˻ظ´
ҩѧר˶É격
ÒѾÓÐ8È˻ظ´
¿ÉÄÜÉϲ»Á˰¶£¿ÓÐÌõ¼þµÄ¿ÉÒÔ¿¼ÂÇÆäËû³ö·
ÒѾÓÐ0È˻ظ´
Gongjinw
½ð³æ (ÕýʽдÊÖ)
- Ó¦Öú: 9 (Ó×¶ùÔ°)
- ½ð±Ò: 485.5
- É¢½ð: 50
- ºì»¨: 1
- Ìû×Ó: 385
- ÔÚÏß: 227.2Сʱ
- ³æºÅ: 1150214
- ×¢²á: 2010-11-18
- ÐÔ±ð: GG
- רҵ: Ò©Îﻯѧ

2Â¥2015-11-17 08:09:24
hudaiqiang
Ìú¸Ëľ³æ (ÖøÃûдÊÖ)
- Ó¦Öú: 7 (Ó×¶ùÔ°)
- ½ð±Ò: 13891.3
- ºì»¨: 11
- Ìû×Ó: 1310
- ÔÚÏß: 151.2Сʱ
- ³æºÅ: 1051312
- ×¢²á: 2010-07-03
- ÐÔ±ð: GG
- רҵ: ºËÎïÀí

3Â¥2015-11-17 11:00:59














¡¢ raltegravir or rilpivirine (Complera®
»Ø¸´´ËÂ¥